AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$OSUR

OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion

ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Investor Contact: Media Contact: Mike Vallie Amy Koch investorinfo@orasure.com media@orasure.com OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion • 14% year-over-year revenue gr

Original reporting
SEC EDGAR 8-K
Published Nov 9, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$OSUR
Bullish
medium confidence
Mentioned
$OSUR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$OSURBullishMed
01

Why it matters

The company posted 14% YoY revenue growth, improved gross margins, and issued guidance for Q4 revenues of $30‑32M, indicating an acceleration of growth in 2027.

02

Market read

First‑report earnings release with updated guidance; likely to influence OSUR stock and related diagnostic peers.

03

What to watch

Potential supply chain constraints for new kits could temper future growth.

Relevance 7/10Novelty 8/10Timing: today

Background

OraSure Technologies (Nasdaq: OSUR) filed a Form 8‑K reporting its Q3 2026 financial results and forward guidance.

Company-level read

Ticker impact

$OSURBullishMedium confidence
Context

OSUR disclosed Q3 2026 results with 14% YoY revenue growth and updated guidance for Q4 2026 revenues of $30‑32M.

Expected impact

likely upward pressure as the market prices in the updated guidance and stronger margins.

Evidence & confidence

New earnings numbers and guidance are primary disclosures; investors typically reward better-than-expected growth and margin expansion.

Market effects

Sector

Positive for the point‑of‑need diagnostics sector, may lift peers with similar product lines.

Regional

Limited to U.S. small‑cap and healthcare markets.

Global

Modest; reflects broader trends in decentralized diagnostics.

Counterpoint

What could challenge this read

If the revenue growth is driven by one‑off product launches, the upside may be limited.

Key entities

  • company
    OraSure Technologies Inc.

    Provider of point‑of‑need and home diagnostic tests.

Read at source← All news

Related articles

$OSURMed

OraSure Technologies Q3 Earnings Call Highlights

OraSure (NASDAQ:OSUR) reported a Q3 GAAP operating loss of $13M and non-GAAP loss of $10.2M. It forecasts Q4 revenue of $30M-$32M, up 12-20% YoY. The company expects full-year revenue growth to accelerate in 2027. OraSure has launched its Ebola 2.0 rapid antigen test and Colli-Pee Dx urine collection kit, with initial sales encouraging. It is working on FDA pre-submission for its InteliQuick CT/NG molecular self-test.

finance.yahoo.com
$OSURMed

OraSure: Q3 Earnings Snapshot

OraSure Technologies (OSUR) reported a Q3 loss of $13.1M, or 19 cents per share. Adjusted losses were 15 cents per share. Revenue was $30.9M. The company expects Q4 revenue between $30M and $32M.

finance.yahoo.com
$OSURMed

OraSure (OSUR) Returns To Profit, But Growth Remains Elusive

OraSure (OSUR) reported Q2 2026 GAAP net income of $6.2M, reversing a $19.7M loss from a year earlier. Revenue rose 9.7% quarter-over-quarter to $30.6M, beating guidance. Gross margins improved, and diagnostics revenue grew 1% YoY. The profit was largely due to a $22.6M accounting adjustment, with underlying losses widening. The company secured two FDA clearances but delayed a product submission. Hedge fund ownership increased, and short interest is 4.79%.

insidermonkey.com
$OSURMedAI 8/10

OraSure (OSUR) Q2 2026 Earnings Call Transcript

OraSure Technologies (OSUR) reported Q2 2026 revenue of $30.6M, up 9.7% sequentially, including $19.4M Diagnostics revenue and $9.9M Sample Management Solutions revenue. GAAP gross margin was 43.5% and GAAP operating income $5.4M. Q3 revenue guidance is $29.5M to $32.5M. Management said FDA clearance for Colli-Pee and EUA for OraQuick Ebola 2.0 were received, while IntelliQ CT/NG submission was withdrawn.

fool.com
$OSURMed

OraSure Announces Second Quarter 2026 Financial Results

ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Investor Contact: Media Contact: investorinfo@orasure.com media@orasure.com OraSure Announces Second Quarter 2026 Financial Results BETHLEHEM, PA, August 5, 2026 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnost

SEC EDGAR 8-K
$OSURMedAI 8/10

OraSure receives Emergency Use Authorization for second generation Ebola test

OraSure Technologies said the U.S. FDA granted Emergency Use Authorization for its second generation OraQuick Ebola 2.0 Rapid Antigen Test. The single-use test detects four Ebola virus types and can use blood or oral fluids. OraSure cited improved sensitivity, longer shelf life, and automated manufacturing, and plans to ramp production. The DRC and Uganda outbreak has 2,473 cases and 999 deaths, per Congo’s Ministry of Health.

wfmz.com